Clinical Trial Update: A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

View source ↗

Summary

This completed clinical trial describes switching from a first- or second-line disease-modifying therapy to Ozanimod in participants with Relapsing-Remitting Mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED